



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 14th November, 2025

To,
Department of Corporate Services (DSC-CRD)
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

Sub: Outcome of Board meeting held today i.e. Friday, November 14, 2025.

Ref.: Norris Medicines Limited, Scrip code: 524414

Dear Sir/Madam,

With reference to above captioned subject, pursuant to Regulation 30 & 33 of Chapter IV read with schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and in continuation to our letter November 08th, 2025, intimating the date of Board Meeting of Norris Medicines Limited ("Company"), we would like to inform you that the Board of Directors at their Meeting held today i.e. Friday, November 14, 2025 inter- alia considered and approved the Un-audited Financial Results along with Limited Review Report for the quarter and half-year ended September 30, 2025.

A copy of the Un-audited Financial Results along with the Limited Review Report of the Auditors thereon issued in this regard is attached as **Annexure I.**

We are arranging to publish the said Financial Results in newspapers in the format prescribed under Regulation 47 of Listing Regulations.

The meeting of Board of Directors commenced at 05:00 p.m. and concluded at 05:30 p.m.

You are requested to take the aforementioned information on your record.

Yours faithfully,


FOR NORRIS MEDICINES LIMITED

VIMAL D. SHAH
DIRECTOR
DIN-01506655



NORRIS

MEDICINES LIMITED



Factory : Plot No. 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com.

CIN No.,L24230GJ1990PLC086581

Rs. In Lakhs

STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2025

Sl. No.	Particulars	QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	(a) Revenue from Operations	200.04	145.66	126.84	345.70	199.33	582.02
	(b) Other Income	0.08	2.38	0.12	2.46	1.28	6.14
	Total Income From Operations (Net)	200.12	148.04	126.96	348.16	200.61	588.15
2	Expenses						
	a. Cost of Materials Consumed	248.24	103.84	17.51	352.08	72.60	337.10
	b. Changes in Inventories of Finished Goods, work in Progress and stock in trade	-76.27	-31.33	75.34	-107.60	37.52	8.06
	c. Employee Benefit Expenses	44.30	41.17	28.95	85.47	63.26	140.72
	d. Finance Costs	10.82	11.15	8.48	21.97	16.93	43.96
	e. Depreciation and Amortisation Expense	12.25	12.25	13.29	24.50	26.47	53.70
	f. Other expenditure	32.60	42.00	19.49	74.60	56.56	122.42
	Total Expenses	271.94	179.08	163.07	451.02	273.34	705.96
3	Profit/ Loss before Tax (1-2)	-71.82	-31.04	-36.11	-102.86	-72.73	-117.81
4	Tax Expense						
	a: Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	b: Deferred Tax	0.00	0.00	0.00	0.00	0.00	5.94
5	Profit / Loss after Tax	-71.82	-31.04	-36.11	-102.86	-72.73	-123.75
6	Other Comprehensive Income						
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-71.82	-31.04	-36.11	-102.86	-72.73	-123.75
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.72	-0.31	-0.36	-1.04	-0.73	-1.24



FOR, NORRIS MEDICINES LTD

AUTHORISED SIGNATORY

STATEMENT OF ASSETS AND LIABILITIES

	As At 30.09.2025 Un audited	As At 31.03.2025 (Audited)
A . ASSETS		
1. Non Current Assets		
a) Property, Plant & Equipment	503.23	526.77
b) Capital Work in Progress		
c) Investment Property		
d) Financial Assets		
i) Investments	0.94	0.95
ii) Loans	3.05	1.99
iii) Others	40.12	41.80
e) Non Current Tax Assets (Net)	90.40	90.40
f) Other Non Current Assets	85.72	84.77
TOTAL NON CURRENT ASSETS	723.46	746.68
2. Current Assets		
a) Inventories	482.28	412.81
b) Financial Assets		
i) Trade Receivables	63.53	140.89
ii) Cash and Cash Equivalents	6.46	3.98
iii) Bank Balance other than "b" above.		
iv) Loans		
v) Others	73.41	76.62
TOTAL CURRENT ASSETS	625.68	634.30
TOTAL ASSETS	1349.14	1380.98
B. EQUITY & LIABILITIES		
1) Equity		
a) Equity Share Capital	992.57	992.58
b) Other Equity	-2582.19	-2,479.33
Total Equity	-1589.62	-1486.75
2) Non Current Liabilities		
a) Financial Liabilities - Borrowings	1843.79	1,852.74
b) Provisions		
c) Deferred Tax Laibilities (Net)		
d) Non Current Tax Liabilities (Net)		
Total Non - Current Liabilities	1843.79	1852.74
3) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	303.41	305.31
ii) Trade payables	307.37	302.55
iii) Other financial liabilities	210.66	133.18
b) Other Current Liabilities	0.00	0.00
c) Provisions	273.53	273.96
Total Current Liabilities	1094.97	1,015.00
TOTAL EQUITY AND LIABILITIES	1349.14	1380.98

Notes:

1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14.11.2025. The above results have been subjected to Audit by the Statutory Auditors of the company .

2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015 and SEBI circular dated 05.07.2016.


3) The Company is having one segment only and therefore Segmental Reporting is not applicable.

4) There are no exceptional/ extraordinary items during the quarter ended 30.09.2025

5) Previous year/ period have been regrouped / rearranged wherever necessary to make them comparable with current period

Date: 14.11.2025

Place: Ankleshwar



For Norris Medicines Limited

Vimal D Shah
Managing Director

BAHEDIA & ASSOCIATES

Chartered Accountants

SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Valia Road,
GIDC, ANKLESHWAR - 393 002. Office : (M) : 84011 20412

CA. B. L. Bahedia

(FCA., LL.B., D.T.P., B.Com.)



Mobile No. : +91 98241 36264, 97252 20412

E-mail : bbahedia@yahoo.com/gmail.com

"Limited Review Report"

To, The Board of Directors of M/S NORRIS MEDICINES LIMITED, ANKLESHWAR-2

We have reviewed the accompanying statement of Un Audited financial results of M/S NORRIS MEDICINES LIMITED, REGD. OFF. At 801/P, GIDC ESTATE, ANKLESHWAR-393002, for the quarter period ended 30th September, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 14/11/2025. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, BAHEDIA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FRN-114421W)



(CA. B.L. BAHEDIA)
PROPRIETOR
(M.NO.048066)

PLACE: ANKLESHWAR
DATE: 14/11/2025



UDIN: -25048066BMIME17404

NORRIS MEDICINES LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 31st September 2025

		30-09-2025	31-03-2025
		Rs. Lakhs	Rs. Lakhs
(A)	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit/Loss before tax and extraordinary items	- 102.86	- 123.75
	Adjustments for :		
	Depreciation & Amortisation	24.50	53.70
	Deferred Tax Liability	-	5.94
	Interest Income	-	1.84
	Interest Paid	21.97	43.96
	Profit/Loss on Investment in bonds	-	-
	Profit/Loss on sale of Fixed Assets	-	-
	Other Non Operating Income	-	-
	OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	- 56.39	- 21.99
	Adjustments for Changes in Working Capital		
	Increase/Decrease in Trade Debtors	77.36	34.84
	Increase/Decrease in Inventories	- 69.46	20.54
	Increase/Decrease in Loans & Advances	3.21	5.14
	Trade Payables and Other Liabilities	79.97	92.44
	Net cash from operations before taxation	91.08	73.00
	Tax Paid	-	-
	CASH FLOW BEFORE EXTRA ORDINARY ITEM	91.08	73.00
	Extra Ordinary Item	-	-
	NET CASH FROM OPERATING ACTIVITIES (A)	34.69	51.01
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	- 0.96	1.90
	Sale of Fixed Assets	-	-
	Investments Made during the year	-	-
	Long Term Advances	- 0.33	0.00
	Receipt from Investment	-	0.33
	Interest Income	-	1.85
	Dividend Received	-	-
	Profit/Loss on sale of bonds	-	-
	Net Cash used in Investing Activities (B)	- 1.29	- 0.38
(C)	CASH FLOW FROM FINANCING ACTIVITIES:-		
	Share Capital	-	-
	Borrowings	- 8.95	6.43
	Interest paid	- 21.97	43.96
	Net Cash Used in Financing Activities (C)	- 30.92	- 50.39
	Net Increase/Decrease in Cash and Cash Equivalents (A+B+C)	2.48	0.22
	Cash and Cash equivalents - Opening balance	3.98	3.76
	Cash and cash equivalents - Closing balance	6.46	3.98
		- 2.48	- 0.22
	Component of Cash & Cash Equivalents		
	Cash on hand	1.17	1.29
	With Banks in Current Accounts	5.29	2.69
		6.46	3.98
<p>Date: 14.11.2025 PLACE: Ankleshwar</p>		<p style="text-align: center;">  For Norris Medicines Limited  Vimal D Shah Managing Director </p>	



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Notes :

- 1 These unaudited standalone financial results of Norris Medicines Limited ("the Company") has been prepared
In accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 along with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
- 2 The Financial Results of the Company for the quarter and half year ended 30th September 2025 have been reviewed and recommended by the audit committee and approved by the board of Directors of the Company in their respective meetings held on 14th November, 2025
- 3 The Figures of the previous year / period have been regrouped wherever necessary.
- 4 The Statutory auditors of the Company have carried out a "Limited Review" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015.
The Statement of deviation or variation in the use of issue proceeds of public issue, rights issue, preferential issue, qualified institutions placement, etc., therefore requisite details is forming part of this results.
- 5 The Company's Operation consists only one segment hence Segment reporting under AS17 is not applicable.
- 6 There are no outstanding defaults on loans and debt securities, therefore statement on the same is not forming part of this results.
- 7 The disclosures of Related Party Transaction is applicable and therefore it is forming part of this results
- 8 The statement on impact of audit qualifications is applicable only for yearly filings, therefore it is not forming part of this results.

Place: Mumbai
Date: 14th November, 2025

By order of the Board of Directors
For Norris Medicines Limited

Vimal D. Shah, Director
(DIN: 01506655)